N-({4-[3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl]phenyl}methyl)propanamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: N-({4-[3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl]phenyl}methyl)propanamide
• 英文别名: N-[[4-[3-(trifluoromethyl)-4,5,6,7-tetrahydroindazol-1-yl]phenyl]methyl]propanamide
• 化学式: C₁₈H₂₀F₃N₃O
• 分子量: 351.372
• InChiKey: VAZGASXHWZKPIU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  46.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  3-(三氟甲基)-4,5,6,7-四氢-1H-吲唑 在 copper(l) iodide 、 trans-1,2-Diaminocyclohexane 、 sodium hydride 、 potassium carbonate 、 三乙胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 19.25h， 生成 N-({4-[3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl]phenyl}methyl)propanamide
  参考文献：
  名称：

  Integration of Lead Optimization with Crystallography for a Membrane-Bound Ion Channel Target: Discovery of a New Class of AMPA Receptor Positive Allosteric Modulators

  摘要：

  A novel series of AMPAR positive modulators is described that were identified by high throughput screening. The molecules of the series have been optimized from a high quality starting point hit to afford excellent developability, tolerability, and efficacy profiles, leading to identification of a clinical candidate. Unusually for an ion channel target, this optimization was integrated with regular generation of ligand-bound crystal structures and uncovered a novel chemotype with a unique and highly conserved mode of interaction via a trifluoromethyl group.

  DOI：

  10.1021/jm100679e

文献信息

• Compounds which potentiate AMPA receptor and uses thereof in medicine
  申请人：Harrison Stephen

  公开号：US20080045532A1

  公开（公告）日：2008-02-21

  Compounds of formula (I) and salts are provided: along with pharmaceutical compositions, uses in medicine, e.g., treating disease or condition mediated by a reduction or imbalance in glutamate receptor function, such as schizophrenia or cognition impairment.

  提供式(I)化合物和盐，以及药物组合物，用于医学上的用途，例如治疗由谷氨酸受体功能减弱或失衡引起的疾病或症状，如精神分裂症或认知障碍。
• Compounds Which Potentiate AMPA Receptor and Uses Thereof in Medicine
  申请人：Harrison Stephen

  公开号：US20090118280A1

  公开（公告）日：2009-05-07

  Compounds of formula (I) and salts are provided: along with pharmaceutical compositions, uses in medicine, e.g., treating disease or condition mediated by a reduction or imbalance in glutamate receptor function, such as schizophrenia or cognition impairment.

  提供式(I)的化合物和盐，以及药物组合物，用于医学用途，例如治疗由谷氨酸受体功能降低或失衡所介导的疾病或病情，如精神分裂症或认知障碍。
• COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE
  申请人：GLAXO GROUP LIMITED

  公开号：EP1996555A1

  公开（公告）日：2008-12-03
• UPREGULATING BDNF LEVELS TO MITIGATE MENTAL RETARDATION
  申请人：LAUTERBORN JULIE

  公开号：US20080139472A1

  公开（公告）日：2008-06-12

  This invention provides methods of preserving, improving, or restoring cognitive function in mammal having one or more mutations in the FMR1 gene (e.g. at risk for or having fragile x syndrome), where the methods involve the brain derived neurotrophic factor (BDNF) level or activity in the brain of said mammal. In certain embodiments the methods involve administering one or more AMPA potentiators (e.g., ampakines) to the mammal in an amount sufficient to increase BDNF levels in the brain of the mammal.
• US7566735B2
  申请人：——

  公开号：US7566735B2

  公开（公告）日：2009-07-28